BRAF: which options do we have for these patients in second line?

BRAF

MUTANT CANCER: PARTICULARITIES

• 2’2% of 9.643 patients

• 22% of all BRAF mutations significantly younger patients, less females

• Low grade left sided tumors

• mOS significantly longer

• Multivariable analysis, non-V600BRAF mutation was independently associated with improved OS (HR, 0.18; p 0.001).